This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Axsome resolves SUNOSI patent litigation
Business patent settlement

Axsome resolves SUNOSI patent litigation

Analysis based on 7 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026

Sentiment
20
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The resolution of patent litigation for Solriamfetol provides clarity and extended market exclusivity for Axsome Therapeutics, which is expected to positively impact its stock price and long-term revenue forecasts. This ensures that generic versions of Solriamfetol will not enter the market until at least March 2040, securing a significant revenue stream for Axsome Therapeutics for an extended period.

Pharmaceuticals Biotechnology
Event Summary

Axsome Therapeutics has announced the resolution of all patent litigation concerning its product Solriamfetol (solriamfetol). These litigations arose from Abbreviated New Drug Applications submitted to the United States — Food and Drug Administration by companies seeking to market generic versions of Solriamfetol. As part of the settlement, Axsome Therapeutics will grant five companies the right to sell generic versions of Solriamfetol starting on or after March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted. The settlement agreement will be submitted to the United States — Federal Trade Commission and the United States — United States Department of Justice for review.

Entities Involved
stock
Axsome Therapeutics
Axsome Therapeutics has resolved all patent litigation related to its product Solriamfetol, securing market exclusivity until at least March 2040, which is positive for its long-term revenue prospects.
Importance 100.0 Sentiment 30.0
oth
Solriamfetol
Solriamfetol is the product at the center of the patent litigation, and its continued market exclusivity is crucial for Axsome Therapeutics's revenue.
Importance 90.0 Sentiment 20.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is involved as the agency that receives Abbreviated New Drug Applications and approves generic versions of drugs.
Importance 40.0 Sentiment 0.0
govactor
United States — Federal Trade Commission
The United States — Federal Trade Commission will review the settlement agreement as required by law.
Importance 30.0 Sentiment 0.0
govactor
United States — United States Department of Justice
The United States — United States Department of Justice will review the settlement agreement as required by law.
Importance 30.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States — United States Department of Justice
United States — Federal Trade Commission related ↔ United States — United States Department of Justice
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.